NHLBI TOPMed - NHGRI CCDG: Atherosclerosis Risk in Communities (ARIC)
Demographics (2)
- Age_at_collection - Subject's age in years at time of tissue collection (phv00541537.v1.p4)
- SEX - Biological sex (phv00541535.v1.p4)
Disease Events (1)
- IN_CVD - Cardiovascular disease group (phv00397017.v2.p4)
Other (29)
- ANALYTE_TYPE - Type of omics assay to be performed, generally one of the following four values: "RNA", "DNA", "protein", or "metabolite" (phv00541544.v1.p4)
- ANALYTE_TYPE - Analyte type (phv00266310.v3.p4)
- Barcode - Illumina chip Sentrix barcode (phv00541545.v1.p4)
- BODY_SITE - Anatomical site at which biosample was taken, e.g. "arm vein", "lung", "inner oral cavity" (phv00541542.v1.p4)
- BODY_SITE - Body site where sample was collected (phv00266309.v3.p4)
- CCDG_SAMPLE_ID - De-identified CCDG Sample ID (phv00493319.v1.p4)
- Collection_visit - Study visit when the primary biosample was collected (relevant for longitudianal studies with multiple waves of clinic visits). (phv00541538.v1.p4)
- Collection_year - Year in which primary biosample was collected (informative for storage time) (phv00541539.v1.p4)
- CONSENT - Consent group (phv00266298.v4.p4)
- decodeDate - Earliest date shown for 'AutoDecode' action in the .idat 'RunInfo' table. Presumably related to the chip manufacturing date. (phv00541547.v1.p4)
- extractDate - Earliest date shown for 'Scan', 'Register' and 'Extract' actions in the .idat 'RunInfo' table. Presumably date when the chip was scanned after hybridization, extension and staining. (phv00541548.v1.p4)
- Funding_Source - Project funding source (phv00397012.v2.p4)
- HISTOLOGICAL_TYPE - Cell or tissue subtype derived from the Primary biosample, or if no subfractionation was done, the primary biosample type; e.g. plasma for proteins and metabolites; PBMC, T-cell, or monocyte for RNA; blood buffy coat for DNA (phv00541543.v1.p4)
- IS_TUMOR - Tumor status of the sample. For non-cancer studies, all values should be "no". For cancer studies, values should be "yes" or "no". (NCBI Biosample characteristic) (phv00541541.v1.p4)
- IS_TUMOR - Tumor status (phv00266311.v3.p4)
- nSNPsRead - Value reported as 'nSNPsRead' in Illumina .idat file header (phv00541546.v1.p4)
- p.0.01 - Fraction of CpG sites which pass a detection p-value threshold of 0.01 (phv00541550.v1.p4)
- p.0.05 - Fraction of CpG sites which pass a detection p-value threshold of 0.05 (phv00541549.v1.p4)
- Primary_biosample_type - Type of primary biosample, e.g. "venous blood", "lung epithelium"; be as specific as possible (phv00541540.v1.p4)
- SAMPLE_ID - TOPMed identifier for each sample aliquot sent to the assay center. MUST use TOPMed identifiers - TOR (RNA), TOP (protein), TOM (metabolite), TOE (DNA for methylation assay) (phv00541536.v1.p4)
- SAMPLE_ID - De-identified Sample ID (phv00266308.v3.p4)
- SAMPLE_ID - De-identified Sample ID (phv00266300.v4.p4)
- SEQUENCING_CENTER - Name of the center which conducted sequencing (phv00397011.v2.p4)
- Study_Name - TOPMed-assigned short study name (1:1 with TOPMed phs number) (phv00397015.v2.p4)
- SUBJECT_ID - De-identified Subject ID (phv00266297.v4.p4)
- SUBJECT_ID - De-identified Subject ID (phv00266299.v4.p4)
- TOPMed_Phase - TOPMed Phase (phv00397013.v2.p4)
- TOPMed_Project - TOPMed Project that funded sequencing (phv00397014.v2.p4)
- VTE_TYPE - Venous thrombus embolism group (phv00397016.v2.p4)